Parkinson's disease (PD) is characterized by the progressive degeneration of dopaminergic nigrostriatal neurons, and reductions in striatal dopamine (DA) levels, dopaminergic synapses, and the density of dendritic spines on striatal medium spiny neurons. No treatment for PD currently available is thought to restore the numbers of dopaminergic nigrostriatal terminals or striatal dendritic spines.
Parkinson's disease (PD) is characterized by the progressive degeneration of dopaminergic nigrostriatal neurons, and reductions in striatal dopamine (DA) levels, dopaminergic synapses, and the density of dendritic spines on striatal medium spiny neurons. No treatment for PD currently available is thought to restore the numbers of dopaminergic nigrostriatal terminals or striatal dendritic spines.
We previously observed that chronic oral administration of two circulating phosphatide precursors, uridine (as UMP) and the omega-3 fatty acid DHA, along with dietary choline, can increase neuronal levels of the phosphatides and of specific proteins that characterize synaptic membranes (Wurtman et al., 2006) , as well as the numbers of dendritic spines, in rodent brain (Sakamoto et al., 2007) . The present report examines the effects of giving these precursors in a rat model of PD with unilateral neurotoxin-induced nigrostriatal damage and impaired DA neurotransmission. In this model 6-hydroxydopamine (6-OHDA), injected into one corpus striatum, causes ipsilateral decreases in DA synthesis and release, and characteristic turning behavior.
Male Sprague-Dawley rats (200-250 g) consumed the control diet (containing 16% protein and 0.1% choline) fortified with UMP (0.5%) and received by daily gavage (1 ml/kg) 300 mg/kg of DHA in 5% gum arabic solution; control rats were gavaged with DHA's vehicle. Three days after the start of UMP/DHA administration, rats were injected with 6-OHDA (8 mg in 2 ml of 0.3% ascorbic acid/0.9% saline) into two different sites within their right striata (Kirik et al., 1998) . In preliminary experiments that used DA levels, TH levels, and TH activity as markers, we found that pretreatment with UMP and DHA did not diminish the initial toxic responses to the 6-OHDA. Hence, subsequent studies used animals killed 28 days after starting UMP/DHA, a period previously shown to reliably increase membrane phosphatides, synaptic proteins (Wurtman et al., 2006) and dendritic spines (Sakamoto et al., 2007) .
Rotational behavior was induced by intraperitoneal injection of d-amphetamine (5 mg/kg) 3 weeks after animals received the 6-OHDA treatment (day 25), and ipsilateral rotations by the rats, videotaped between 15 and 45 min following the d-amphetamine injection, were counted by two blind observers. Animals were sacrificed 3 days after testing for rotational behavior. Striatal DA was measured using an HPLC assay (Wang et al., 2005) , and TH activity was determined by a radiometric method (Ulus and Wurtman, 1976) . Striatal phospholipids were extracted and individual phospholipid classes were separated and quantified 0 -monophosphate (UMP) and docosahexaenoic acid (DHA) increases synaptic membranes (as characterized by pre-and post-synaptic proteins) and dendritic spines in rodents. We examined their effects on rotational behavior and dopaminergic markers in rats with partial unilateral 6-hydroxydopamine (6-OHDA)-induced striatal lesions. Rats receiving UMP, DHA, both, or neither, daily, and intrastriatal 6-OHDA 3 days after treatment onset, were tested for d-amphetamine-induced rotational behavior and dopaminergic markers after 24 and 28 days, respectively. UMP/DHA treatment reduced ipsilateral rotations by 57% and significantly elevated striatal dopamine, tyrosine hydroxylase (TH) activity, TH protein and synapsin-1 on the lesioned side. Hence, giving uridine and DHA may partially restore dopaminergic neurotransmission in this model of Parkinson's disease.
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